Alligator Bioscience (Nasdaq Stockholm: ATORX) – On 16 February 2018, at 08:00 am CET, Alligator Bioscience will publish its report for the year ended 31 December 2017. All interested parties are invited to participate in a telephone conference, which will include a presentation of the Full Year Report, on the same day at 1:15 PM CET. The event will be hosted by CEO Per Norlén and the presentation will be held in English.
When: 1:15 pm CET Friday 16 February 2018
To participate in the telephone conference, please use the dial in details shown below:
The presentation can also be reached at:
The conference call will be made available on the company´s website after the call: http://www.alligatorbioscience.com.
For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95
The information was submitted for publication, through the agency of the contact person set out above, at 1:30 p.m. CET on 12 February 2018.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and preclinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit www.alligatorbioscience.com.